Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMeprobamate
Identification
- Name
- Meprobamate
- Accession Number
- DB00371 (APRD01095)
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
- Structure
Structure for DB00371 (Meprobamate)
- Synonyms
- Meprobamat
- Meprobamato
- Meprobamatum
- Meprobamic acid
- External IDs
- DEA No. 2820
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo Meprobamate Tab 400mg Tablet 400 mg Oral Apotex Corporation 1975-12-31 2001-10-09 Canada 
Equanil Tablets 400mg Tablet 400 mg Oral Wyeth Ayerst Canada Inc. 1994-12-31 2000-03-07 Canada Meditran 400mg Tablet 400 mg Oral Medic Laboratory LtÉe 1959-12-31 1996-09-09 Canada Meprobamate Tab 400mg Tablet 400 mg Oral Pro Doc Limitee 1959-12-31 2001-10-15 Canada Meprobamate Tab 400mg Tablet 400 mg Oral Duchesnay Inc. 1978-12-31 2001-10-15 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Meprobamate Tablet 200 mg/1 Oral Alembic Pharmaceuticals Limited 2013-07-23 Not applicable US 
Meprobamate Tablet 200 mg/1 Oral Alembic Pharmaceuticals Limited 2015-12-01 Not applicable US Meprobamate Tablet 400 mg/1 Oral Taro Pharmaceutical Industries, Ltd. 2011-05-23 Not applicable US Meprobamate Tablet 200 mg/1 Oral Taro Pharmaceuticals U.S.A., Inc. 2011-05-23 Not applicable US Meprobamate Tablet 400 mg/1 Oral Actavis Pharma Company 1973-05-03 Not applicable US Meprobamate Tablet 200 mg/1 Oral Avera Mc Kennan Hospital 2015-11-03 2018-06-13 US Meprobamate Tablet 400 mg/1 Oral Dr Reddy's Laboratories 2008-01-03 Not applicable US Meprobamate Tablet 200 mg/1 Oral Taro Pharmaceutical Industries, Ltd. 2011-05-23 Not applicable US Meprobamate Tablet 400 mg/1 Oral Heritage 2009-05-01 2018-01-13 US Meprobamate Tablet 400 mg/1 Oral Alembic Pharmaceuticals Limited 2015-12-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End 282 Mep Tab Meprobamate (200 mg) + Acetylsalicylic acid (350 mg) + Caffeine citrate (30 mg) + Codeine phosphate (15 mg) Tablet Oral Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1959-12-31 1998-08-14 Canada Equagesic Tablets Meprobamate (200 mg) + Acetylsalicylic acid (250 mg) + Ethoheptazine citrate (75 mg) Tablet Oral Wyeth Ayerst Canada Inc. 1995-12-31 1997-01-14 Canada - International/Other Brands
- Equanil (Wyeth) / Meprospan / Miltown (Wallace Laboratories)
- Categories
- UNII
- 9I7LNY769Q
- CAS number
- 57-53-4
- Weight
- Average: 218.2502
Monoisotopic: 218.126657074 - Chemical Formula
- C9H18N2O4
- InChI Key
- NPPQSCRMBWNHMW-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
- IUPAC Name
- 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate
- SMILES
- CCCC(C)(COC(N)=O)COC(N)=O
Pharmacology
- Indication
For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
- Associated Conditions
- Pharmacodynamics
Meprobamate is an anxiolytic drug. It was the best selling minor tranquilizer for a time but has largely been replaced by benzodiazepines. Meprobamate has most of the pharmacological effects and dangers of the barbiturates (though it was marketed as being safer). However, it is less sedating at effective doses. It is reported to have some anticonvulsant properties against absence seizures, but can exacerbate generalized tonic-clonic seizures. It has also been used as a hypnotic (sleeping pill). However, its is currently only licensed as an anxiolytic and it is a third or fourth-order choice.
- Mechanism of action
Meprobamate's mechanism of action is not known. It has been shown in animal studies to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Meprobamate binds to GABAA receptors which interrupt neuronal communication in the reticular formation and spinal cord, causing sedation and altered perception of pain.
Target Actions Organism AGamma-aminobutyric acid receptor subunit alpha-1 agonistHuman AGamma-aminobutyric acid receptor subunit alpha-2 agonistHuman AGamma-aminobutyric acid receptor subunit alpha-3 agonistHuman AGamma-aminobutyric acid receptor subunit alpha-4 agonistHuman AGamma-aminobutyric acid receptor subunit alpha-5 agonistHuman AGamma-aminobutyric acid receptor subunit alpha-6 agonistHuman AGABA-A receptor (anion channel) positive allosteric modulatorHuman - Absorption
Well absorbed from the gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic.
- Route of elimination
- Not Available
- Half life
Plasma half-life is about 10 hours.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. Death has been reported with ingestion of as little as 12 g meprobamate and survival with as much as 40 g.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Capecitabine Metabolism Pathway Drug metabolism Capecitabine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole. Experimental Abiraterone The metabolism of Meprobamate can be decreased when combined with Abiraterone. Approved Acepromazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Meprobamate is combined with Adipiplon. Investigational Afatinib The serum concentration of Afatinib can be increased when it is combined with Meprobamate. Approved Agomelatine The risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Meprobamate is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Meprobamate is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Meprobamate is combined with Alfentanil. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Meprobamate is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Meprobamate is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Meprobamate is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Meprobamate is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Meprobamate is combined with Amperozide. Experimental Apalutamide The serum concentration of Meprobamate can be decreased when it is combined with Apalutamide. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole. Approved, Investigational Armodafinil The metabolism of Meprobamate can be decreased when combined with Armodafinil. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Meprobamate is combined with Asenapine. Approved Azaperone The risk or severity of adverse effects can be increased when Meprobamate is combined with Azaperone. Investigational, Vet Approved Azelastine Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Meprobamate is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Meprobamate is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Benzocaine. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Meprobamate is combined with Benzyl alcohol. Approved Bortezomib The metabolism of Meprobamate can be decreased when combined with Bortezomib. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Meprobamate. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved Bromazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Bupivacaine. Approved, Investigational Buprenorphine Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Meprobamate is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Meprobamate is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Meprobamate is combined with Canertinib. Investigational Carbamazepine The metabolism of Meprobamate can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Meprobamate is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol. Approved Cetirizine The risk or severity of adverse effects can be increased when Meprobamate is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chloramphenicol The metabolism of Meprobamate can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlordiazepoxide. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Meprobamate can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The metabolism of Meprobamate can be decreased when combined with Cimetidine. Approved, Investigational Cinchocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine. Approved, Vet Approved Citalopram The metabolism of Meprobamate can be decreased when combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Meprobamate is combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Meprobamate is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Meprobamate is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Meprobamate is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Meprobamate is combined with Clothiapine. Experimental Clotrimazole The metabolism of Meprobamate can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Meprobamate. Approved Cocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Meprobamate. Approved Cyclizine The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine. Approved Cyproterone acetate The serum concentration of Meprobamate can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate. Approved Dabrafenib The serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Meprobamate is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine. Investigational Delavirdine The metabolism of Meprobamate can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Meprobamate is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane. Approved Desipramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Meprobamate is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Meprobamate is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Diazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Meprobamate is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Meprobamate is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Meprobamate is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin. Approved, Investigational Doxofylline The serum concentration of Doxofylline can be decreased when it is combined with Meprobamate. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Meprobamate. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Meprobamate is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Meprobamate is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Meprobamate is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Meprobamate is combined with Ecopipam. Investigational Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Meprobamate. Approved Efavirenz The metabolism of Meprobamate can be decreased when combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Meprobamate is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Meprobamate is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Meprobamate can be decreased when combined with Eslicarbazepine acetate. Approved Esomeprazole The metabolism of Meprobamate can be decreased when combined with Esomeprazole. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone. Approved, Investigational Ethanol Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Meprobamate is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Meprobamate is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine. Illicit, Vet Approved Etravirine The metabolism of Meprobamate can be decreased when combined with Etravirine. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Meprobamate. Approved Ezogabine The risk or severity of adverse effects can be increased when Meprobamate is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Meprobamate is combined with Fexofenadine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluanisone. Experimental Fluconazole The metabolism of Meprobamate can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam. Approved, Illicit Fluoxetine The metabolism of Meprobamate can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine. Approved Flurazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate. Approved Fluvoxamine The metabolism of Meprobamate can be decreased when combined with Fluvoxamine. Approved, Investigational Fosphenytoin The metabolism of Meprobamate can be increased when combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Meprobamate is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Meprobamate is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gemfibrozil The metabolism of Meprobamate can be decreased when combined with Gemfibrozil. Approved Gepirone The risk or severity of adverse effects can be increased when Meprobamate is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Meprobamate is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Meprobamate is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital. Approved Hydrocodone Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved Iloperidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Meprobamate can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Meprobamate is combined with Indiplon. Investigational Isocarboxazid The therapeutic efficacy of Meprobamate can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Meprobamate is combined with Isoflurane. Approved, Vet Approved Isoniazid The metabolism of Meprobamate can be decreased when combined with Isoniazid. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Meprobamate can be decreased when combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Meprobamate is combined with Lamotrigine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Meprobamate. Approved Levetiracetam The risk or severity of adverse effects can be increased when Meprobamate is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Meprobamate is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Meprobamate is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol. Approved Lidocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Lidocaine. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium. Approved Lobeglitazone The metabolism of Meprobamate can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Meprobamate is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Meprobamate can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Meprobamate can be increased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Meprobamate is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate. Approved Lormetazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Meprobamate can be increased when it is combined with Lorpiprazole. Approved Loxapine The risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine. Approved Luliconazole The serum concentration of Meprobamate can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Meprobamate can be decreased when it is combined with Lumacaftor. Approved Lurasidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Meprobamate can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Meprobamate is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meprobamate is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Medetomidine. Vet Approved Mefloquine The therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Meprobamate is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Meprobamate is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine. Approved, Vet Approved Meptazinol The risk or severity of adverse effects can be increased when Meprobamate is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Meprobamate is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Meprobamate is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital. Approved Methotrimeprazine Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Meprobamate is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital. Approved Metyrosine Meprobamate may increase the sedative activities of Metyrosine. Approved Mianserin The therapeutic efficacy of Meprobamate can be decreased when used in combination with Mianserin. Approved, Investigational Midazolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Midazolam. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved, Investigational Mirtazapine Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Moclobemide The metabolism of Meprobamate can be decreased when combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Meprobamate can be decreased when combined with Modafinil. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Meprobamate. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Meprobamate. Approved Nefazodone The risk or severity of adverse effects can be increased when Meprobamate is combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Meprobamate can be decreased when combined with Nelfinavir. Approved Nicardipine The metabolism of Meprobamate can be decreased when combined with Nicardipine. Approved, Investigational Nicotine The metabolism of Meprobamate can be decreased when combined with Nicotine. Approved Nitrazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Meprobamate is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Meprobamate is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Meprobamate. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine. Approved Omeprazole The metabolism of Meprobamate can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Ondansetron The risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Meprobamate is combined with Opium. Approved, Illicit Orlistat The serum concentration of Meprobamate can be decreased when it is combined with Orlistat. Approved, Investigational Orphenadrine Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam. Approved Oxprenolol The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone. Approved Pantoprazole The metabolism of Meprobamate can be decreased when combined with Pantoprazole. Approved Paraldehyde Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Meprobamate. Approved Penfluridol The risk or severity of adverse effects can be increased when Meprobamate is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved Perazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Meprobamate is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine. Approved Pethidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Meprobamate is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Meprobamate is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Meprobamate is combined with Phenoxyethanol. Approved Phenytoin The metabolism of Meprobamate can be increased when combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Meprobamate is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Meprobamate is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Meprobamate is combined with Pomalidomide. Approved Pramipexole Meprobamate may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Meprobamate can be decreased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Meprobamate is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Meprobamate is combined with Proxibarbal. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Meprobamate. Approved PSD502 The risk or severity of adverse effects can be increased when Meprobamate is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Meprobamate is combined with Quetiapine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Meprobamate is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon. Approved, Investigational Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Meprobamate. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Meprobamate. Approved, Investigational Rifampicin The metabolism of Meprobamate can be increased when combined with Rifampicin. Approved Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Meprobamate. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Meprobamate is combined with Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Meprobamate is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Romifidine. Vet Approved Ropinirole Meprobamate may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Ropivacaine. Approved Rotigotine Meprobamate may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Meprobamate can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Meprobamate. Approved Scopolamine The risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Meprobamate is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Meprobamate is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The metabolism of Meprobamate can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane. Approved, Vet Approved Silodosin The serum concentration of Silodosin can be increased when it is combined with Meprobamate. Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved Stiripentol The metabolism of Meprobamate can be decreased when combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Meprobamate is combined with Sultopride. Experimental Suvorexant Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Meprobamate is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. Approved Tasimelteon The risk or severity of adverse effects can be increased when Meprobamate is combined with Tasimelteon. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrodotoxin. Investigational Thalidomide Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Meprobamate is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Meprobamate can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone. Approved, Withdrawn Topiramate The metabolism of Meprobamate can be decreased when combined with Topiramate. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Meprobamate. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Meprobamate is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Meprobamate is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Meprobamate is combined with Valproic Acid. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Meprobamate is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Meprobamate is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Meprobamate is combined with Vigabatrin. Approved Vincristine The excretion of Vincristine can be decreased when combined with Meprobamate. Approved, Investigational Vinyl ether The risk or severity of adverse effects can be increased when Meprobamate is combined with Vinyl ether. Experimental Voriconazole The metabolism of Meprobamate can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Meprobamate is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Meprobamate is combined with Xylazine. Vet Approved Yohimbine The therapeutic efficacy of Meprobamate can be decreased when used in combination with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate. Approved Zolazepam The risk or severity of adverse effects can be increased when Meprobamate is combined with Zolazepam. Vet Approved Zolpidem Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Meprobamate is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Meprobamate is combined with Zotepine. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Meprobamate can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Take without regard to meals. Avoid alcohol.
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014515
- KEGG Drug
- D00376
- PubChem Compound
- 4064
- PubChem Substance
- 46508142
- ChemSpider
- 3924
- ChEBI
- 6761
- ChEMBL
- CHEMBL979
- Therapeutic Targets Database
- DAP001507
- PharmGKB
- PA450377
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Meprobamate
- ATC Codes
- N05CX01 — Meprobamate, combinations
- N05CX — Hypnotics and sedatives in combination, excl. barbiturates
- N05C — HYPNOTICS AND SEDATIVES
- N05 — PSYCHOLEPTICS
- N — NERVOUS SYSTEM
- MSDS
- Download (52.6 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Glaxosmithkline llc
- Medpointe pharmaceuticals medpointe healthcare inc
- Wyeth ayerst laboratories
- Ferndale laboratories inc
- Alra laboratories inc
- Teva pharmaceuticals usa inc
- Alembic ltd
- Barr laboratories inc
- Elkins sinn div ah robins co inc
- Heather drug co inc
- Impax laboratories inc
- Invagen pharmaceuticals inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Ivc industries inc dba inverness medical nutritionals group
- Lannett co inc
- Lederle laboratories div american cyanamid co
- Km lee laboratories inc
- Mallard inc
- Mk laboratories inc
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Nexgen pharma inc
- Parke davis div warner lambert co
- L perrigo co
- Pharmavite pharmaceuticals
- Purepac pharmaceutical co
- Private formulations inc
- Roxane laboratories inc
- Sandoz inc
- Scherer laboratories inc
- Solvay pharmaceuticals
- Stanlabs pharmaceutical co sub simpak corp
- Tablicaps inc
- Usl pharma inc
- Valeant pharmaceuticals international
- Vangard laboratories inc div midway medical co
- Watson laboratories inc
- West ward pharmaceutical corp
- Whiteworth towne paulsen inc
- Halsey drug co inc
- Packagers
- C.O. Truxton Inc.
- Calvin Scott and Co. Inc.
- Dispensing Solutions
- Doctor Reddys Laboratories Ltd.
- GlaxoSmithKline Inc.
- Group Health Cooperative
- Heritage Pharmaceuticals
- InvaGen Pharmaceuticals Inc.
- Major Pharmaceuticals
- Mikart Inc.
- Nexgen Pharma Inc.
- PD-Rx Pharmaceuticals Inc.
- Prescript Pharmaceuticals
- Qualitest
- United Research Laboratories Inc.
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral Tablet Oral 400 mg Tablet Oral 200 mg/1 Tablet Oral 400 mg/1 Tablet Oral 200 mg - Prices
Unit description Cost Unit Mepron 750 mg/5ml Suspension 5.41USD ml Mepron 750 mg/5 ml suspension 4.95USD ml Meprobamate 200 mg tablet 1.42USD tablet Meprobamate 400 mg tablet 0.84USD tablet Meprozine 50-25 mg capsule 0.78USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US6649659 Yes 1997-01-10 2017-01-10 US US4981874 No 1992-08-15 2009-08-15 US CA2152615 No 2001-10-16 2013-12-23 Canada CA1336266 No 1995-07-11 2012-07-11 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 105 °C PhysProp water solubility 4700 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 0.70 HANSCH,C ET AL. (1995) logS -1.67 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 2.47 mg/mL ALOGPS logP 1.06 ALOGPS logP 0.93 ChemAxon logS -2 ALOGPS pKa (Strongest Acidic) 15.17 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 104.64 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 53.04 m3·mol-1 ChemAxon Polarizability 22.65 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9534 Blood Brain Barrier + 0.9864 Caco-2 permeable - 0.5731 P-glycoprotein substrate Non-substrate 0.5282 P-glycoprotein inhibitor I Non-inhibitor 0.8781 P-glycoprotein inhibitor II Non-inhibitor 0.9033 Renal organic cation transporter Non-inhibitor 0.945 CYP450 2C9 substrate Non-substrate 0.9108 CYP450 2D6 substrate Non-substrate 0.8961 CYP450 3A4 substrate Non-substrate 0.7032 CYP450 1A2 substrate Non-inhibitor 0.8381 CYP450 2C9 inhibitor Non-inhibitor 0.8799 CYP450 2D6 inhibitor Non-inhibitor 0.8764 CYP450 2C19 inhibitor Non-inhibitor 0.8754 CYP450 3A4 inhibitor Non-inhibitor 0.8735 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8914 Ames test Non AMES toxic 0.8706 Carcinogenicity Non-carcinogens 0.7304 Biodegradation Not ready biodegradable 0.965 Rat acute toxicity 2.4075 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9943 hERG inhibition (predictor II) Non-inhibitor 0.9322
Spectra
- Mass Spec (NIST)
- Download (10.1 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Carbamate esters
- Alternative Parents
- Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Carbonyl group
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA4
- Uniprot ID
- P48169
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-4
- Molecular Weight
- 61622.645 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA6
- Uniprot ID
- Q16445
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-6
- Molecular Weight
- 51023.69 Da
References
- Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327]
- Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
- Kind
- Protein group
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- ChEMBL Compound Report Card [Link]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on June 16, 2018 22:04